Furthermore, alongside the increasing prevalence of related cardiometabolic diseases such as diabetes, obesity and chronic kidney disease (CKD), the number of people with HF has increased to around 64 million globally, amongst whom most are also living with type 2 diabetes or obesity ( Within the past 2 decades, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as effective agents to improve glycaemic control in type 2 diabetes and to reduce body weight in people with overweight or obesity (Sattar et al., 2021
The GLP-1 receptor agonists are drugs that mimic a natural hormone known as glucagon-like peptide-1, or GLP-1, which the body produces to regulate blood sugar and appetite
These agonists not only enhance GLP-1 release but also suppress the expression of pro-inflammatory cytokines, including IL-2, IL-17a, interferon-, and TNF- (Yusta et al., 2015)
Effectively managing digestive side effects can significantly improve your treatment experience and adherence to GLP-1 therapy
Fiala GJ, Gomes AQ, Silva-Santos B
In short, while GLP-1s themselves dont inherently make you tired, the metabolic changes and side effects they trigger can lead to temporary fatigue for some users
/assets/images/provider/photos/2533448.png)
